Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy

Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy

Abstract Aims/Introduction Small dense low‐density lipoprotein (sdLDL) is a more potent atherogenic lipoprotein than LDL. As sdLDL‐cholesterol (C) levels are determined by triglyceride and LDL‐C levels, pemafibrate and statins can reduce sdLDL‐C levels. However, it remains unclear whether adding pem...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Tsutomu Hirano, Toshiyuki Hayashi, Hiroe Sugita, Atsuko Tamasawa, Satoshi Goto, Masako Tomoyasu, Takeshi Yamamoto, Makoto Ohara, Michishige Terasaki, Hideki Kushima, Yasuki Ito, Sho‐ichi Yamagishi, Yusaku Mori
Формат:	Өгүүллэг
Хэл сонгох:	English
Хэвлэсэн:	Wiley 2023-12-01
Цуврал:	Journal of Diabetes Investigation
Нөхцлүүд:	Pemafibrates Small dense low‐density lipoprotein Type 2 diabetes
Онлайн хандалт:	https://doi.org/10.1111/jdi.14076

Ижил төстэй зүйлс

Case series showing the safety and changes in lipid profiles of hemodialysis patients with hypertriglyceridemia after pemafibrate administration
-н: Rino Okada, зэрэг
Хэвлэсэн: (2024-12-01)

Efficacy of Pemafibrate in Comparison to Fenofibrate and Bezafibrate on Triglyceride Levels and Liver, and Renal Functions in Patients With Hypertriglyceridemia and Type 2 Diabetes
-н: Junko Oya, зэрэг
Хэвлэсэн: (2023-11-01)

Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia
-н: Masahiro Kikuchi, зэрэг
Хэвлэсэн: (2024-09-01)

Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study
-н: Hiroshi Nomoto, зэрэг
Хэвлэсэн: (2023-06-01)

Effect and safety of pemafibrate for patients with type 2 diabetes mellitus and hypertriglyceridemia: a retrospective analysis of clinical data
-н: Aki Okamoto, зэрэг
Хэвлэсэн: (2025-02-01)

Pemafibrate prevents choroidal neovascularization in a mouse model of neovascular age-related macular degeneration
-н: Deokho Lee, зэрэг
Хэвлэсэн: (2023-01-01)

Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage
-н: Hiroshi Nomoto, зэрэг
Хэвлэсэн: (2023-10-01)

Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion
-н: Shigeki Kitamura, зэрэг
Хэвлэсэн: (2023-09-01)

Long-Term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD
-н: Takanobu Iwadare, зэрэг
Хэвлэсэн: (2024-05-01)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis
-н: Shizuya Yamashita, зэрэг
Хэвлэсэн: (2023-05-01)

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients
-н: Ryosuke Sugimoto, зэрэг
Хэвлэсэн: (2023-02-01)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
-н: Takeshi Hatanaka, зэрэг
Хэвлэсэн: (2021-10-01)

Pemafibrate Prevents Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms
-н: Naofumi Amioka, зэрэг
Хэвлэсэн: (2022-06-01)

Lessons from PROMINENT and prospects for pemafibrate
-н: Jean-Charles Fruchart, зэрэг
Хэвлэсэн: (2024-07-01)

Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis
-н: Kazufumi Dohmen, зэрэг
Хэвлэсэн: (2021-10-01)

Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)
-н: Yasutaka Takeda, зэрэг
Хэвлэсэн: (2023-03-01)

The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)
-н: Yasutaka Takeda, зэрэг
Хэвлэсэн: (2023-01-01)

Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up
-н: Suguru Ikeda, зэрэг
Хэвлэсэн: (2021-12-01)

Pemafibrate Protects against Fatty Acid-Induced Nephropathy by Maintaining Renal Fatty Acid Metabolism
-н: Daiki Aomura, зэрэг
Хэвлэсэн: (2021-06-01)

Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice
-н: Zhe Zhang, зэрэг
Хэвлэсэн: (2022-07-01)

Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect
-н: Azuma Watanabe, зэрэг
Хэвлэсэн: (2023-10-01)

Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD
-н: Takanobu Iwadare, зэрэг
Хэвлэсэн: (2022-11-01)

Evaluation of the effects of pemafibrate on metabolic dysfunction‐associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis‐4 index and the magnetic resonance imaging‐aspartate aminotransferase score
-н: Takeshi Ichikawa, зэрэг
Хэвлэсэн: (2023-12-01)

Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose
-н: Satoshi Shinozaki, зэрэг
Хэвлэсэн: (2025-02-01)

Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study
-н: Hidekatsu Yanai, зэрэг
Хэвлэсэн: (2022-02-01)

Impact of pemafibrate in patients with metabolic dysfunction‐associated steatotic liver disease complicated by dyslipidemia: A single‐arm prospective study
-н: Hiroki Ono, зэрэг
Хэвлэсэн: (2024-04-01)

Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling
-н: Yusaku Mori, зэрэг
Хэвлэсэн: (2019-10-01)

Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study
-н: Satoshi Shinozaki, зэрэг
Хэвлэсэн: (2023-06-01)

The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis
-н: Hideki Kushima, зэрэг
Хэвлэсэн: (2017-10-01)

Effect of statin add-on therapy on cardiovascular mortality
-н: John R. Nelson, зэрэг
Хэвлэсэн: (2024-03-01)

Emphysematous cystitis in an elderly Japanese patient with type 2 diabetes mellitus
-н: Hironori Yashima, зэрэг
Хэвлэсэн: (2019-03-01)

Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus
-н: Feher M, зэрэг
Хэвлэсэн: (2013-01-01)

Comparison of positive rates between glutamic acid decarboxylase antibodies and ElisaRSR™ 3 Screen ICA™ in recently obtained sera from patients who had been previously diagnosed with slowly progressive type 1 diabetes
-н: Nobuaki Takehana, зэрэг
Хэвлэсэн: (2023-07-01)

Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease
-н: Shotaro Kamata, зэрэг
Хэвлэсэн: (2023-08-01)

Glucose-Dependent Insulinotropic Polypeptide Suppresses Foam Cell Formation of Macrophages through Inhibition of the Cyclin-Dependent Kinase 5-CD36 Pathway
-н: Michishige Terasaki, зэрэг
Хэвлэсэн: (2021-07-01)

Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice
-н: Michishige Terasaki, зэрэг
Хэвлэсэн: (2017-01-01)

Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism
-н: G. S. Mal’
Хэвлэсэн: (2005-06-01)

Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.
-н: Michishige Terasaki, зэрэг
Хэвлэсэн: (2015-01-01)

Analysis of serum levels and DNA methylation of fibroblast growth factor 21 using peripheral blood-derived genomes in patients with obesity
-н: Hiroyuki Shinozaki, зэрэг
Хэвлэсэн: (2024-09-01)

No change in small low‐density lipoprotein cholesterol levels with pemafibrate might explain the negative results of the PROMINENT trial
-н: Tsutomu Hirano
Хэвлэсэн: (2023-04-01)